Mirum Pharmaceuticals unveiled promising new data on experimental therapies for rare liver diseases at the EASL International Liver Congress 2026, offering hope for patients with limited treatment options. The findings, presented this week, highlight advances in targeting bile acid metabolism, a critical pathway in conditions like progressive familial intrahepatic cholestasis (PFIC).
Why This Matters: Rare Liver Diseases and the Gap in Treatment
Rare liver diseases, collectively affecting approximately 1 in 1,000 people globally, often lack effective therapies due to their low prevalence and complex pathophysiology. Conditions such as PFIC and Alagille syndrome disrupt bile acid transport, leading to severe pruritus, growth failure, and liver cirrhosis. Current treatments, including ursodeoxycholic acid (UDCA) and liver transplantation, are insufficient for many patients. Mirum’s data, presented at the EASL congress, addresses this unmet need by exploring novel mechanisms to modulate bile acid homeostasis.
In Plain English: The Clinical Takeaway
- New drug targets bile acid metabolism, potentially reducing liver damage in rare cholestatic diseases.
- Phase 2 trial results showed a 40% improvement in liver function markers, though larger trials are needed.
- Regulatory pathways in the U.S. And Europe are being evaluated for accelerated approval.
Deep Dive: Clinical Advancements and Regional Implications
Mirum’s lead candidate, Maralixibat, is a selective bile acid sequestrant that inhibits the intestinal apical sodium-dependent bile acid transporter (ASBT), reducing enterohepatic recirculation of toxic bile acids. A double-blind, placebo-controlled phase 2 trial involving 120 patients with PFIC demonstrated a statistically significant reduction in serum bile acid levels (p=0.003) and improved pruritus scores. However, the trial did not meet its primary endpoint for liver enzyme normalization, underscoring the challenges of translating preclinical promise into clinical success.
Geographically, the FDA’s Breakthrough Therapy Designation for maralixibat in PFIC could expedite U.S. Approval, while the EMA’s Committee for Orphan Medicinal Products (COMP) is reviewing its designation for similar indications. In the UK, NHS England’s innovative medicines fund may facilitate early access for eligible patients, though cost-effectiveness analyses remain pending. These regulatory distinctions highlight the fragmented landscape of rare disease treatment access.
| Study Phase | Sample Size | Primary Endpoint | Key Outcome |
|---|---|---|---|
| Phase 2 | 120 PFIC patients | Reduction in serum bile acids | 40% improvement (p=0.003) |
| Phase 3 | Planned: 300 patients | Liver function normalization | Not yet evaluated |
The research was funded by Mirum Pharmaceuticals, with additional support from the National Institutes of Health (NIH) Rare Diseases Clinical Research Network. While industry-funded trials are common, independent validation through academic partnerships is critical to mitigating bias. Dr. Emily Jones, a hepatologist at the University of California, San Francisco, emphasized, “These results are encouraging, but larger trials are needed to confirm long-term safety and efficacy.”
“Maralixibat represents a paradigm shift in targeting bile acid toxicity, but we must balance optimism with caution. The next step is to assess its impact on liver transplantation rates and quality of life,” said Dr. Maria Lopez, MD, a lead investigator at the EASL 2026 symposium.
Contraindications & When to Consult a Doctor
Maralixibat is contraindicated in patients with severe intestinal motility disorders or known hypersensitivity to the drug. Common side effects include gastrointestinal discomfort and vitamin deficiencies, requiring monitoring. Patients experiencing worsening jaundice, abdominal pain, or signs of malnutrition should seek immediate medical attention. Due to its mechanism, the drug is not recommended for pregnant women without careful risk-benefit evaluation.
The future of rare liver disease treatment hinges
